Health News

Tibotec Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies. Both ARTEMIS and TITAN evaluated the efficacy and safety of PREZISTA with ritonavir (r) vs…

Read more

Filed under: Pharmacy News
Tags: Drug, HIV, Pharmacy

Related posts

• University of Western Ontario receives FDA approval to begin SAV001 HIV trial (0)
  The first and only preventative HIV vaccine based on a genetically modified killed whole virus has received approval by the United States Food and Drug Administration (FDA) to start human clinical trials. Read more [tags] Pharmacy News [/tags]
  
  
• UNITAID Concerned About Infant HIV Medication Shortage, Drug Company Says Supply Is Sufficient (0)
  Bristol-Myers Squibb's plans this month to close its plant in Meymac, France, that manufactures "the last therapeutic option" for HIV-positive babies has drawn criticism from UNITAID, Reuters reports. In an open letter published in the Lancet (... Read more [tags] Pharmacy News [/tags]
  
  
• U-M scientists identify new reservoir for hidden HIV-infected cells that can serve as factory for new infections (0)
  University of Michigan scientists have identified a new reservoir for hidden HIV-infected cells that can serve as a factory for new infections. The findings, which appear online March 7 in Nature Medicine, indicate a new target for curing the disease so those infected with the virus may someday no longer rely on AIDS drugs for [...]
  
  
• Truvada deemed safe & effective in HIV infection risk reduction (0)
  Gilead Sciences Inc's Truvada pills are deemed safe and effective for reducing the risk of HIV infection, U.S. regulators said on Tuesday. But they recommended a cautious approach for using the drug in efforts to prevent the virus that causes AIDS. Read more [tags] Pharmacy News [/tags]
  
  
• Tibotec submits NDA for TMC278 anti-HIV compound to FDA (0)
  Tibotec Pharmaceuticals today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), being studied for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults. If approved, TMC278 will be the third anti-HIV compound to be introduced [...]